CCL20 in the tumor microenvironment: implications for cancer progression and therapeutic approaches
Clinical & Translational Oncology,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 22, 2025
Abstract
Increasing
knowledge
of
the
immunosuppressive
tumor
microenvironment
in
cancer-related
processes
has
led
to
developing
novel
immune-based
therapies
that
have
changed
cancer
treatment
paradigm.
In
microenvironment,
plethora
soluble
factors
secreted
by
cells
interacts
with
immune
and
non-immune
components
deliver
signals
necessary
for
progression.
Accordingly,
targeting
tumor-derived
inducing
this
become
an
appealing
therapeutic
potential
advancing
treatment.
CCL20,
a
chemokine
best
known
induce
leucocyte
migration
response
pathological
inflammatory
conditions,
been
implicated
proliferation,
angiogenesis,
metastasis,
immunosuppression,
resistance.
Notably,
CCL20
its
receptor
CCR6
are
important
interactions.
This
review
discusses
interaction
between
CCL20–CCR6
axis
how
these
interactions
promote
Also,
outline
studies
utilizing
combination
other
standard
treatments
shed.
Язык: Английский
Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy
Cellular Oncology,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 25, 2025
Tumor-infiltrating
myeloid
cells
(TIMs),
which
encompass
tumor-associated
macrophages
(TAMs),
neutrophils
(TANs),
myeloid-derived
suppressor
(MDSCs),
and
dendritic
(TADCs),
are
of
great
importance
in
tumor
microenvironment
(TME)
integral
to
both
pro-
anti-tumor
immunity.
Nevertheless,
the
phenotypic
heterogeneity
functional
plasticity
TIMs
have
posed
challenges
fully
understanding
their
complexity
roles
within
TME.
Emerging
evidence
suggested
that
presence
is
frequently
linked
prevention
cancer
treatment
improvement
patient
outcomes
survival.
Given
pivotal
function
TME,
recently
been
recognized
as
critical
targets
for
therapeutic
approaches
aimed
at
augmenting
immunostimulatory
cell
populations
while
depleting
or
modifying
those
immunosuppressive.
This
review
will
explore
important
properties
related
immunity,
angiogenesis,
metastasis.
We
also
document
latest
strategies
targeting
preclinical
clinical
settings.
Our
objective
illustrate
potential
immunological
may
improve
existing
treatments.
Язык: Английский
Focal adhesion kinase-mediated interaction between tumor and immune cells in the tumor microenvironment: implications for cancer-associated therapies and tumor progression
Clinical & Translational Oncology,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 13, 2024
Язык: Английский
18F-FDG PET/CT predicts the prognosis of patients with hepatocellular carcinoma undergoing liver transplantation
Liver Cancer,
Год журнала:
2025,
Номер
unknown, С. 1 - 27
Опубликована: Март 5, 2025
In
addition
to
radical
resection,
liver
transplantation
(LTx)
is
an
effective
treatment
for
hepatocellular
carcinoma
(HCC).
However,
tumor
recurrence
limits
the
efficacy
of
LTx
in
some
patients.
This
study
investigated
role
18F-fludeoxyglucose
(18F-FDG)
positron
emission
tomography/computed
tomography
(PET/CT)
predicting
prognosis
patients
with
HCC
after
LTx.
A
total
278
consecutive
who
underwent
pre-LTx
PET/CT
were
divided
into
derivation
(n
=
178)
and
temporal
validation
100)
cohorts
evaluated
values,
immunohistochemical
(IHC)
findings,
DNA
sequencing
tissues.
Patients
post-LTx
exhibited
significantly
higher
maximum
standardized
uptake
values
(SUVmax)
scans.
Receiver
operating
characteristic
curve
analyses
identified
SUVmax
ratio
(TSUVmax/LSUVmax)
as
strongest
predictor
recurrence,
optimal
cutoff
value
1.43.
Kaplan-Meier
demonstrated
that
a
TSUVmax/LSUVmax
>1.43
was
associated
shorter
time
(TTR)
overall
survival
(OS)
both
(p
<
0.001
both).
Multivariate
Cox
regression
confirmed
independent
risk
factor
cohorts.
IHC
revealed
correlated
Ki-67
CK19
expression.
indicated
tumors
had
more
mutations
TMB.
Furthermore,
TP53,
EPPK1,
MDM4,
SLAMF7,
SDHC,
B4GALT3,
RXRG,
FCGR
family
genes,
well
TP53
PI3K
signaling-related
alterations.
The
preoperative
potential
following
Its
use
improves
candidate
selection
management.
Язык: Английский
The Tumor Microenvironment as a Therapeutic Target in Cutaneous T Cell Lymphoma
Cancers,
Год журнала:
2024,
Номер
16(19), С. 3368 - 3368
Опубликована: Окт. 1, 2024
Cutaneous
T
cell
lymphomas
(CTCLs)
are
a
heterogeneous
group
of
non-Hodgkin
lymphomas,
with
mycosis
fungoides
and
Sézary
syndrome
being
the
two
common
subtypes.
Despite
substantial
improvement
in
early-stage
diagnosis
treatments,
some
patients
still
progress
to
advanced
stage
an
elusive
underpinning
mechanism.
While
this
unsubstantiated
disease
mechanism
coupled
diverse
clinical
outcomes
poses
challenges
management,
emerging
evidence
has
implicated
tumor
microenvironment
process,
thus
revealing
promising
therapeutic
potential
targeting
microenvironment.
Notably,
malignant
cells
can
shape
their
dampen
antitumor
immunity,
leading
Th2-dominated
responses
that
promote
progression.
This
is
largely
orchestrated
by
alterations
cytokines
expression
patterns,
genetic
dysregulations,
inhibitory
effects
immune
checkpoint
molecules,
immunosuppressive
cells.
Herein,
recent
insights
into
determining
factors
CTCL
support
progression
have
been
highlighted.
Also,
advances
strategies
target
micromovement
rationale
improving
treatment
efficacy
discussed.
Язык: Английский